AU1520097A - Ob protein derivatives having prolonged half-life - Google Patents

Ob protein derivatives having prolonged half-life

Info

Publication number
AU1520097A
AU1520097A AU15200/97A AU1520097A AU1520097A AU 1520097 A AU1520097 A AU 1520097A AU 15200/97 A AU15200/97 A AU 15200/97A AU 1520097 A AU1520097 A AU 1520097A AU 1520097 A AU1520097 A AU 1520097A
Authority
AU
Australia
Prior art keywords
protein
immunoglobulin
ofthe
derivative
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15200/97A
Other languages
English (en)
Inventor
Frederic J. De Sauvage
Nancy Levin
Richard L Vandlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU15200/97A priority Critical patent/AU1520097A/en
Publication of AU1520097A publication Critical patent/AU1520097A/en
Priority to AU18291/01A priority patent/AU769250B2/en
Priority claimed from AU18291/01A external-priority patent/AU769250B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU15200/97A 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life Abandoned AU1520097A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU15200/97A AU1520097A (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life
AU18291/01A AU769250B2 (en) 1995-12-27 2001-02-05 OB protein derivatives having prolonged half-life

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57949495A 1995-12-27 1995-12-27
US579494 1995-12-27
US66718496A 1996-06-20 1996-06-20
US667184 1996-06-20
PCT/US1996/020718 WO1997024440A1 (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life
AU15200/97A AU1520097A (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life
AU18291/01A AU769250B2 (en) 1995-12-27 2001-02-05 OB protein derivatives having prolonged half-life

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU18291/01A Division AU769250B2 (en) 1995-12-27 2001-02-05 OB protein derivatives having prolonged half-life

Publications (1)

Publication Number Publication Date
AU1520097A true AU1520097A (en) 1997-07-28

Family

ID=27077779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15200/97A Abandoned AU1520097A (en) 1995-12-27 1996-12-19 Ob protein derivatives having prolonged half-life

Country Status (14)

Country Link
EP (1) EP0870026B1 (enExample)
JP (1) JP4037905B2 (enExample)
CN (1) CN1154726C (enExample)
AT (1) ATE267255T1 (enExample)
AU (1) AU1520097A (enExample)
BR (1) BR9612359A (enExample)
CA (1) CA2238307A1 (enExample)
CZ (1) CZ9802013A3 (enExample)
DE (1) DE69632546T2 (enExample)
IL (1) IL124831A0 (enExample)
MX (1) MX9804687A (enExample)
NZ (1) NZ326592A (enExample)
RU (1) RU2178307C2 (enExample)
WO (1) WO1997024440A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
AU2002300605B2 (en) * 1997-04-17 2005-05-12 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU5606098A (en) * 1996-12-20 1998-07-17 Amgen, Inc. Ob fusion protein compositions and methods
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
JP4380067B2 (ja) 1998-04-23 2009-12-09 味の素株式会社 抗血栓活性物質及びグリコカリシンの検出法
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
AU2002252035A1 (en) * 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MXPA05006994A (es) 2002-12-27 2005-10-18 Diobex Inc Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
PL1699822T3 (pl) 2003-12-30 2008-08-29 Merck Patent Gmbh Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
PT1699821E (pt) 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
CA2591297C (en) 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
CN104147596A (zh) * 2013-05-14 2014-11-19 李荣秀 生物药非共价结合聚合物延长治疗浓度的方法及用途
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
AU2002300605B2 (en) * 1997-04-17 2005-05-12 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods

Also Published As

Publication number Publication date
WO1997024440A1 (en) 1997-07-10
JP2000504210A (ja) 2000-04-11
EP0870026B1 (en) 2004-05-19
CZ9802013A3 (cs) 1998-09-16
CA2238307A1 (en) 1997-07-10
JP4037905B2 (ja) 2008-01-23
MX9804687A (es) 1998-10-31
DE69632546T2 (de) 2005-06-30
BR9612359A (pt) 1999-07-13
RU2178307C2 (ru) 2002-01-20
EP0870026A1 (en) 1998-10-14
CN1205738A (zh) 1999-01-20
DE69632546D1 (de) 2004-06-24
NZ326592A (en) 2001-05-25
IL124831A0 (en) 1999-01-26
CN1154726C (zh) 2004-06-23
ATE267255T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
US6620413B1 (en) OB protein-polymer chimeras
AU1520097A (en) Ob protein derivatives having prolonged half-life
AU721129B2 (en) WSX receptor and ligands
AU2006244497B2 (en) Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU781460B2 (en) Glycosylated leptin compositions and related methods
CZ20012406A3 (cs) Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů
AU2011265482B2 (en) Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU2013263717B2 (en) Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU769250B2 (en) OB protein derivatives having prolonged half-life
AU784477B2 (en) Nucleic acid construct for optimized production of products
US20060205660A1 (en) OB protein-immunoglobulin chimeras
AU2004200586B2 (en) Novel CTLA4/CD28 ligands and uses therefor
AU5339500A (en) Novel CTLA4/CD28 ligands and uses therefor
HK1190311A (en) Trimeric ox40-immunoglobulin fusion protein and methods of use

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted